The use of combination drug therapy in the treatment of hypertension.
Data from the National Health and Nutritional Examination Survey and from the World Health Organization have clearly demonstrated that, worldwide, less than one quarter of hypertensive patients are adequately controlled by our currently accepted blood pressure (BP) goals. These patients remain at significant risk for the development of cardiovascular disease. Although, there are multiple reasons contributing to inadequate blood pressure control, the most important include: 1) patient compliance; 2) acceptance of inadequate BP control by clinicians; 3) lower BP goals; and 4) the fact that it is very difficult or impossible to achieve adequate BP control with monotherapy in the majority of patients. The use of combination therapy, either as first-line treatment or much earlier in the course of treating hypertensive patients, may provide the solution to many of these management problems. Low-dose combination therapy provides several advantages in that: 1) it will be more effective than monotherapy due to the additive effect on BP of complementary drugs; 2) it will provide 24-hour efficacy with once-a-day dosing since most of the low-dose combination drugs include long-acting components; 3) it will have a higher response rate than monotherapy and will be effective in most subgroups of hypertensive patients due to the complementary nature of combination therapy; 4) it may have fewer metabolic side effects than higher dose monotherapy since metabolic side effects also tend to be dose dependent; 5) it may have fewer dose-dependent side effects than monotherapy, as BP control is obtained at lower doses of each of the component drugs; 6) it is more convenient than monotherapy; 7) it may cost less, since low-dose combination therapy tends to be a little more expensive than each of the components but cheaper than if each of the components were used separately. For these reasons, the use of low-dose combination therapy as first-line treatment or much earlier in the stepped-care approach may play a major role in improving the dismal control rates in hypertensive patients, which may ultimately have a positive impact on the rate of development of cardiovascular disease.